title: Erratum to: 'Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.
authors: Sarah Cannon Research Institute and the Tennessee Oncology, PLLC, 250 25th Avenue North, Suite 100, Nashville, TN, 37203, USA. dyardley@tnonc.com.
authors: Denise A
authors: DA
authors: Yardley
authors: University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
authors: Adam
authors: A
authors: Brufsky
authors: Weston Park Hospital, Sheffield Cancer Research Center, Sheffield, England.
authors: Robert E
authors: RE
authors: Coleman
authors: Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, and Istituto Oncologico Veneto IRCCS, Padova, Italy.
authors: Pierfranco F
authors: PF
authors: Conte
authors: Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
authors: Javier
authors: J
authors: Cortes
authors: Celgene Corporation, Summit, NJ, USA.
authors: Stefan
authors: S
authors: Glück
authors: Centre de Lutte Contre le Cancer d'Auvergne, Clermont Ferrand, France.
authors: Jean-Mark A
authors: JM
authors: Nabholtz
authors: Texas Oncology-Baylor Charles A. Sammons Center; US Oncology, Dallas, TX, USA.
authors: Joyce
authors: J
authors: O'Shaughnessy
authors: Celgene Corporation, Summit, NJ, USA.
authors: Robert M
authors: RM
authors: Beck
authors: Celgene Corporation, Summit, NJ, USA.
authors: Amy
authors: A
authors: Ko
authors: Celgene Corporation, Summit, NJ, USA.
authors: Markus F
authors: MF
authors: Renschler
authors: Celgene Corporation, Summit, NJ, USA.
authors: Debora
authors: D
authors: Barton
authors: Breast Center, University of Munich, Munich, Germany.
authors: Nadia
authors: N
authors: Harbeck